Skip to main content
. 2024 Mar 26;12(3):e008011. doi: 10.1136/jitc-2023-008011

Figure 4.

Figure 4

(A) Fold change in HLA-DR+CD38+CD8+ T cells following two cycles of immunotherapy across Group A patients (≥20% infusions before noon) and Group B patients (<20% infusions before noon). (B) Clinical response per immune-modified Response Evaluation Criteria in Solid Tumors. CR, complete response; PD, progression of disease; PR, partial response; SD, stable disease.